Rockland Trust Co. Has $7.81 Million Position in Bristol Myers Squibb Company $BMY

Rockland Trust Co. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 173,075 shares of the biopharmaceutical company’s stock after selling 10,127 shares during the period. Rockland Trust Co.’s holdings in Bristol Myers Squibb were worth $7,806,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. First National Trust Co raised its holdings in Bristol Myers Squibb by 41.6% in the 3rd quarter. First National Trust Co now owns 53,564 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 15,742 shares in the last quarter. Navellier & Associates Inc. increased its position in shares of Bristol Myers Squibb by 45.6% during the third quarter. Navellier & Associates Inc. now owns 13,251 shares of the biopharmaceutical company’s stock valued at $598,000 after purchasing an additional 4,151 shares during the period. Arista Wealth Management LLC raised its stake in shares of Bristol Myers Squibb by 36.5% in the third quarter. Arista Wealth Management LLC now owns 13,653 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 3,649 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in Bristol Myers Squibb by 0.9% in the third quarter. Oppenheimer & Co. Inc. now owns 245,797 shares of the biopharmaceutical company’s stock worth $11,085,000 after purchasing an additional 2,091 shares during the period. Finally, Linden Thomas Advisory Services LLC boosted its stake in Bristol Myers Squibb by 1.5% during the third quarter. Linden Thomas Advisory Services LLC now owns 28,214 shares of the biopharmaceutical company’s stock worth $1,272,000 after buying an additional 416 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 2.0%

BMY stock opened at $60.75 on Tuesday. The business has a fifty day moving average price of $54.57 and a 200 day moving average price of $49.12. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a market capitalization of $123.67 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 0.19 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Morgan Stanley restated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday. HSBC reissued a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.